-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$20.78298.85% Upside
Revance Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Revance Therapeutics, Inc.?
Revance Therapeutics, Inc. has been rated by research analysts at Mizuho Securities, Piper Sandler, H.C. Wainwright, Needham, Barclays, Wells Fargo in the past 90 days.